NASDAQ:QLGN Qualigen Therapeutics (QLGN) Stock Price, News & Analysis $1.66 +0.25 (+17.73%) As of 09/23/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsSEC Filings About Qualigen Therapeutics Stock (NASDAQ:QLGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Qualigen Therapeutics alerts:Sign Up Key Stats Today's Range$1.42▼$1.7050-Day Range$0.65▼$1.5552-Week Range$1.61▼$8.81Volume990,956 shsAverage Volume1.52 million shsMarket Capitalization$2.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Qualigen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. The company’s research programs are centered on small-molecule and other targeted therapeutic approaches intended to address biological mechanisms associated with tumor growth and disease progression. Qualigen’s development pipeline has included QN-302, an investigational small-molecule therapy being studied for potential use in oncology, including pancreatic cancer. The company has also pursued additional preclinical and clinical programs aimed at treating cancers and rare diseases. These products remain investigational and require further clinical development and regulatory review before they can be commercialized. The company is based in the United States and has roots in the diagnostics industry through its predecessor and affiliated operations. Qualigen Therapeutics became the successor to Ritter Pharmaceuticals following a 2020 corporate transaction involving Qualigen, Inc. Its current business is primarily focused on advancing its therapeutic pipeline rather than providing established commercial medical products.AI Generated. May Contain Errors. Read More Qualigen Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks0th Percentile Overall ScoreQLGN MarketRank™: Qualigen Therapeutics scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingQualigen Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageQualigen Therapeutics has received no research coverage in the past 90 days.Read more about Qualigen Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Qualigen Therapeutics is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Qualigen Therapeutics is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for QLGN. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQualigen Therapeutics does not currently pay a dividend.Dividend GrowthQualigen Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Qualigen Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Qualigen Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders1.80% of the stock of Qualigen Therapeutics is held by insiders.Percentage Held by Institutions3.18% of the stock of Qualigen Therapeutics is held by institutions.Read more about Qualigen Therapeutics' insider trading history. Receive QLGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Qualigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QLGN Stock News HeadlinesQualigen Therapeutics (NASDAQ:QLGN) Trading Up 1.8% - Time to Buy?September 23 at 1:41 AM | americanbankingnews.comQualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville, Plans to Develop AS1411 for the Treatment of COVID-19December 13, 2025 | cnn.comThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Chaikin Money Flow indicator has a new top retirement pick. The company holds three fast-growing businesses -- including an autonomous vehicle unit and a streaming service with 10x Netflix's reach -- any of which could be spun off in the next 12 to 24 months. It also pays a dividend, a rarity among high-growth AI names. Chaikin lays out the full case in a new free presentation, no email or credit card required.September 24 at 1:00 AM | Chaikin Analytics (Ad)Qualigen Therapeutics Rebrands to AIxCrypto HoldingsNovember 17, 2025 | msn.comQualigen Therapeutics stockholders approve all proposals with majority voteNovember 17, 2025 | msn.comFaraday Future Becomes Majority Shareholder in Qualigen Therapeutics, Preparing for Corporate Rebranding and Strategic Transformation on November 20November 16, 2025 | quiverquant.comQQualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 StrategyNovember 16, 2025 | globenewswire.comQualigen Therapeutics to rebrand as AIxCryptoOctober 28, 2025 | msn.comSee More Headlines QLGN Stock Analysis - Frequently Asked Questions How have QLGN shares performed this year? Qualigen Therapeutics' stock was trading at $2.34 at the start of the year. Since then, QLGN shares have decreased by 29.1% and is now trading at $1.66. How were Qualigen Therapeutics' earnings last quarter? Qualigen Therapeutics, Inc. (NASDAQ:QLGN) posted its earnings results on Friday, November, 14th. The company reported ($4.68) earnings per share (EPS) for the quarter. When did Qualigen Therapeutics' stock split? Shares of Qualigen Therapeutics reverse split before market open on Tuesday, November 5th 2024.The 1-50 reverse split was announced on Friday, November 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did Qualigen Therapeutics IPO? Qualigen Therapeutics (QLGN) raised $44 million in an initial public offering (IPO) on Friday, June 19th 2015. The company issued 4,000,000 shares at a price of $10.00-$12.00 per share. How do I buy shares of Qualigen Therapeutics? Shares of QLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Qualigen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Qualigen Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Zomedica (ZOM), Bank of America (BAC), Wells Fargo & Company (WFC), JPMorgan Chase & Co. (JPM) and Abbott Laboratories (ABT). Company Calendar Last Earnings11/14/2025Today9/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorTechnology Industry Software Sub-IndustryApplication Software Current SymbolNASDAQ:QLGN CIK1460702 Webwww.qualigeninc.com Phone(760) 918-9165FaxN/AEmployees50Year Founded1996Profitability EPS (Trailing Twelve Months)($7.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.26 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-202.16% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.12) per share Price / Book-0.40Miscellaneous Outstanding Shares1,695,000Free Float1,664,000Market Cap$2.81 million OptionableNot Optionable Beta0.24 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:QLGN) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
